Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 104 clinical trials
Safety of a Single Administration of AAV2hAQP1 an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

Background Radiation can cause the parotid salivary glands to make less saliva (dry mouth). This can cause problems like infections and tooth decay. Researchers hope a new drug can help people with dry mouth caused by radiation. Objectives To examine the safety of AAV2hAQP1 gene therapy. To see if the …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 11 Nov, 2020
  • 1 location
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

preparative regimen
hemoglobin s
graft versus host disease
George Washington University School of Medicine
 (5.4 away) Contact site
  • 27 May, 2020
  • +19 other locations
Functional Connectivity as a Biomarker of rTMS

Background Traumatic brain injury (TBI) damages the connections between brain cells. This can lead to problems like memory loss. Repetitive transcranial magnetic stimulation (rTMS) can help improve connections between brain areas in healthy people. Researchers want to see if it can be useful in patients with memory problems after TBI. …

transcranial magnetic stimulation
memory impairment
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 02 Jul, 2020
  • 1 location
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or …

flow cytometry
Georgetown University Medical Center
 (7.9 away) Contact site
  • 02 Sep, 2020
  • +32 other locations
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

This is a non-randomized clinical trial of gene transfer using a self-inactivating, insulated, lentiviral gene transfer vector to treat 23 patients with X-linked severe combined immunodeficiency (XSCID, also called SCID-X1) who are between 2 and 40 years of age; who do not have a tissue matched sibling who can donate …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 18 Nov, 2020
  • 1 location
PEN-866 in Patients With Advanced Solid Malignancies

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

pancreatic adenocarcinoma
primary cancer
National Institutes of Health / National Cancer Institute
 (9.7 away) Contact site
  • 21 Nov, 2020
  • +9 other locations
Brentuximab Vedotin for Systemic Sclerosis

There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin, a drug-antibody conjugate approved for the treatment of lymphoma and targeted to the protein CD30 molecule expressed on activated immune cells There is …

raynaud's syndrome
immunosuppressive agents
Georgetown University Medical Center: Division of Rheumatology
 (5.8 away) Contact site
  • 04 Nov, 2020
  • +9 other locations
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

The primary objectives of this study are: To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). To evaluate the efficacy of magrolimab in combination with …

large b-cell lymphoma
b-cell lymphoma
follicular lymphoma
hodgkin's disease
 (9.4 away) Contact site
  • 26 Oct, 2020
  • +16 other locations
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

Georgetown Lombardi Comprehensive Cancer Center
 (7.8 away) Contact site
  • 15 Jul, 2020
  • +2 other locations
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Background Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Two types are embryonal RMS (ERMS) and alveolar RMS (ARMS). Dasatinib may block over-expression of a certain enzyme. Ganitumab may block a certain growth factor, which might suppress tumor growth. This drug combination may help slow tumor growth …

alveolar rhabdomyosarcoma
neutrophil count
biological therapy
monoclonal antibodies
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 27 Nov, 2020
  • +1 other locations